Understanding how aggressive cell states emerge in castration-resistant prostate cancer
Official title: Investigating targetable mechanisms of altered cell states in castration-resistant prostate cancer
Funded at State University New York Stony Brook · NIH-11463275 · Data updated 2026-11-12
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $498,775 |
| NIH project number | 1R01CA296366-01A1 |
| Project ID | NIH-11463275 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with prostate cancer who may develop resistance to androgen-deprivation therapy or who have tumors showing early signs of resistant cell states.
✕Less likely to help
Patients whose cancer does not rely on the identified resistant cell states may not benefit directly.
What this research studies
This project looks at why some prostate cancer cells change into resistant forms that survive after therapies that lower testosterone. Researchers will analyze single-cell data to identify specific markers and pathways that support these dangerous cell states. By understanding how these subtypes evolve, scientists hope to find new targets to prevent resistance and improve treatments for men with prostate cancer. The work is designed to inform the design of future therapies that could keep cancer under control for longer.
Why it matters
Potential benefit: If successful, the work could lead to new treatment strategies that prevent or overcome resistance in prostate cancer.
How similar studies have gone: Preliminary single-cell studies have shown diverse cell states in tumors, suggesting targeted strategies could be effective, but translation to therapy remains ongoing.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Talos, Flaminia — State University New York Stony Brook
- Study coordinator: Talos, Flaminia
Related research
Other NIH-funded projects on the same topics.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
-
Stopping therapy-resistant prostate cancer by blocking FOXA2 and AP-1
This research looks at whether blocking a protein switch called FOXA2 and its partner AP‑1 can stop or reverse prostate cancers that no longer respond to hormone therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.